摘要
本文讨论了基于抗肿瘤坏死因子特异生物治疗长期疗效的免疫药理学指南背后的基本原理。“关于为什么不能仅依靠临床结果来制定治疗决策的一些争论被提出。对此,核心问题是诊断治疗学的使用(即,功能性抗肿瘤坏死因子药物和抗药物抗体的监控和循环水平)能够显著改善治疗,因为该疗法可以根据患者个体量身订制,并且提供更有效、更经济的临床效益,同时使副作用的风险最小化。大量关于患者个体肿瘤坏死因子生物药品药动学的免疫药理学知识也会有助于生产更有效和更安全的肿瘤坏死因子抑制剂”[1]
关键词: 抗肿瘤坏死因子抗体,抗肿瘤坏死因子治疗,克罗恩病,最优化,抗肿瘤坏死因子的低水平,溃疡性结肠炎
Current Drug Targets
Title:Pharmacokinetics in IBD: Ready for Prime Time?
Volume: 15 Issue: 11
Author(s): Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, Amelie Moreau, Jean Marc Phelip, Christian Genin, Dominique Lamarque and Stephane Paul
Affiliation:
关键词: 抗肿瘤坏死因子抗体,抗肿瘤坏死因子治疗,克罗恩病,最优化,抗肿瘤坏死因子的低水平,溃疡性结肠炎
摘要: This review discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with anti-TNF-α specific biotherapies. “Arguments why therapeutic decision-making should not rely on clinical outcomes alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term clinical benefits while minimising risk of side effects. Large-scale immunopharmacological knowledge of the pharmacokinetics of TNF-α biopharmaceuticals in individual patients would also help industry to develop more effective and safer TNF-α inhibitors” [1].
Export Options
About this article
Cite this article as:
Roblin Xavier, Rinaudo Melanie, Sparrow Peter Miles, Moreau Amelie, Phelip Marc Jean, Genin Christian, Lamarque Dominique and Paul Stephane, Pharmacokinetics in IBD: Ready for Prime Time?, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140829153509
DOI https://dx.doi.org/10.2174/1389450115666140829153509 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design Monocyclic and Fused Azines and Azoles as Histamine H<sub>4</sub> Receptor Ligands
Current Medicinal Chemistry Molecules to Selectively Target Receptors for Treatment of Pain and Neurogenic Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Validated UPLC-MS Method for Pharmacokinetic Investigations of Cyclosporine-A in Blood
Current Pharmaceutical Analysis Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Regenerative Potential of Stem Cells Derived from Human Exfoliated Deciduous (SHED) Teeth during Engineering of Human Body Tissues
Current Stem Cell Research & Therapy Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?
Current Pharmaceutical Design Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Methotrexate Hepatotoxicity in Children with Juvenile Idiopathic Arthritis: A Single-Center Study
Current Rheumatology Reviews The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research Recent Trends in Design and Developments of New Drugs for the Treatment of Cancer, Rheumatoid arthritis, and Parkinson’s Disease-Associated to Abnormal Signal Transduction
Current Signal Transduction Therapy Pharmaceutical Polymeric Nanoparticles Prepared by the Double Emulsion- Solvent Evaporation Technique
Recent Patents on Drug Delivery & Formulation Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery